Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma Clinical Trial

— INFINITE  

Official title:

A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03710876
• Other study ID #: rAd-IFN-MM-301
• Secondary ID: 2017-003169-82
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: January 21, 2019
• Est. completion date: November 2024

Study information

• Verified date: October 2021
• Source: Trizell Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen. Eligible patients will be randomized 1:1 to either: 1. Treatment group: rAd-IFN + Celecoxib followed by Gemcitabine 2. Control group: Celecoxib followed by Gemcitabine Patients randomized to the treatment group will receive rAd-IFN administered into the pleural space via an Intrapleural catheter (IPC) or similar intrapleural device on study Day 1. The primary objective of this study is to compare the overall survival (OS) associated with rAd IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM

Description:

TITLE: A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma PROTOCOL NUMBER: rAd-IFN-MM-301 STUDY DRUGS: Nadofaragene firadenovec (Recombinant adenovirus vector containing the human interferon alpha-2b gene: rAd-IFN), celecoxib, and gemcitabine PHASE: 3 INDICATION: Malignant pleural mesothelioma (MPM) SPONSOR: Trizell, Ltd. SITES: Approximately 80 sites globally OBJECTIVES: The primary objective of this study is to compare the overall survival (OS) associated with rAd IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen. The secondary objectives of this study are: - To compare between rAd-IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen, with respect to: - Survival rate at 12 months and every 6 months thereafter; - Progression-free survival (PFS); - Best response (complete response, partial response, or stable disease); and - Safety of rAd-IFN; and - To evaluate rAd-IFN, when administered with celecoxib and gemcitabine, in a sub-set of patients with MPM who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen, with respect to viral shedding and biodistribution. The exploratory objectives of this study are: • To compare between rAd-IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen, with respect to: - Health-related Quality-of-Life, - The relationship between immunological status and response to treatment, and - Biocorrelates of response to treatment. POPULATION: The population for this study is patients with histologically confirmed MPM of epithelioid or biphasic (predominantly [>50%] epithelioid) histology who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen. STUDY DESIGN AND DURATION: The study is an open-label, randomized, parallel group study conducted in patients with histologically confirmed MPM of epithelioid or biphasic (predominantly [>50%] epithelioid) histology who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen. Screening assessments must be completed within 28 days of Study Day 1, and eligible patients will be randomized to either: 1. Treatment group: rAd-IFN (Study Day 1) + celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/early termination [ET]); or 2. Control group: celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/ET). Treatment Phase Patients randomized to receive rAd-IFN (treatment group) will have an intrapleural catheter (IPC) or other intrapleural access device previously in place or inserted for the study, permitting drug administration to an accessible pleural space. The rAd-IFN will be diluted to a volume of 25 mL using sterile normal saline and will be administered directly to the pleural space via the IPC or similar device. Patients will receive gemcitabine until disease progression/ET. All adverse events will be captured from the time of the main study's informed consent through 30 days after the last dose of study treatment (rAd-IFN, celecoxib, and/or gemcitabine). All treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) will be followed until resolution or stabilization. Survival Follow-Up Phase Following disease progression, patients will be followed every 3 months for survival. All previously recorded TEAEs and SAEs will be followed until resolution or stabilization. DOSAGE FORMS AND ROUTE OF ADMINISTRATION: Patients randomized to the treatment group will receive rAd-IFN (3 × E11 viral particles) on Day 1 of the study, diluted to a total volume of 25 mL using sterile normal saline and administered into the pleural space via an IPC or similar intrapleural device. All study patients (treatment and control) will receive: - Celecoxib administered at a dose of 400 mg twice daily orally on Days 1 to 14 of the study; and - Gemcitabine starting on Study Day 14, using the following treatment regimen: 1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day gemcitabine cycle and continued every 3 weeks until disease progression/ET. STATISTICAL ANALYSES: The primary analysis of the primary endpoint is a comparison of the OS curves between the 2 groups using a log-rank test. The log-rank test will be stratified using the same variables used for stratifying the randomization. Secondary analyses of the primary endpoint will include a comparison of the survival rates at various time points since randomization and a comparison of the median survival times. The effect of baseline covariates will be assessed by constructing a proportional hazard model. Exploratory analyses will include comparison of the survival curves by methods that do not rely on proportional hazards. Secondary time-to-event endpoints will be analyzed in the same manner as the primary efficacy endpoint. Categorical efficacy endpoints will be summarized and compared between groups using a Pearson's test, with the effect of baseline covariates assessed using logistic regression. The nature, incidence, severity, relatedness, expectedness, seriousness, and outcome of TEAEs will be summarized by treatment group for safety analyses. There are 2 interim analyses planned: - Analysis for futility will be assessed upon reaching 123 deaths (estimated to occur 27 months after first patient first visit [FPFV]). Approximately half of the available Beta will be spent at this interim; and - Analysis for efficacy will be assessed upon reaching 234 deaths (estimated to occur 45 months after FPFV). Approximately one-fifth of the available Alpha will be spent at this interim. The final analysis will be assessed upon reaching 267 deaths (estimated to occur 60 months after FPFV). SAMPLE SIZE DETERMINATION: The planned sample size is approximately 300 patients. Based on a 1:1 randomization between treatment groups, a 2.5% one-sided significance level, and a predicted survival at 18 months of 35% in the rAd-IFN treatment group versus 20% in the control group, the study will have at least 90% power (after adjusting for the interim analyses) to detect a statistically significant difference between the treatment groups in the primary endpoint using the log-rank test. The calculation was based on the assumptions that recruitment is uniform over 3 years and that all alive patients are followed-up for 2 years after the end of recruitment. DATA AND SAFETY MONITORING BOARD: An independent Data and Safety Monitoring Board (DSMB) will be convened for this study to monitor safety, efficacy, and study integrity. All aspects of the DSMB's scope of review and procedures will be detailed in a DSMB charter.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 53
• Est. completion date: November 2024
• Est. primary completion date: November 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria Patients who meet all of the following criteria will be eligible to participate in the

study:

1. Aged 18 years or older at the time of consent;

2. Able to give informed consent;

3. Has a confirmed histological diagnosis of MPM with histological type epithelioid or biphasic (if biphasic, histology must be predominantly [50%] epithelioid). Histological diagnosis of MPM will be confirmed centrally using specimens or slides from tumor specimens obtained at the time of initial presentation or a subsequent procedure. Central confirmation of diagnosis with immunohistochemistry will be performed, and independent central confirmation will be required for study entry;

4. Measurable disease, per modified Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 (see Section 7) for pleural mesothelioma;

5. Has received a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, which may have been chemotherapeutic and/or immunotherapeutic treatment regimens for MPM which included at least 1 anti-folate and platinum combination regimen;

• Adjuvant or neoadjuvant therapy represent 1 line of therapy each;
• Patients who have undergone primary surgical resection and/or radiation therapy to the pulmonary site are eligible to participate. For clarity, surgical resection and/or radiation therapy to the pulmonary site are not exclusionary and are not considered a line of therapy;
• Treatment that is split between pre-surgical resection and post-surgical resection and is the same regimen will be counted as 1 regimen. Patients meeting this condition should be discussed with the Medical Monitor prior to including the patient in the study;

6. Has a pleural space accessible for IPC or similar device insertion. Patients with a previously inserted IPC or similar device may be enrolled, and the pre-existing IPC or similar device can be used for vector administration as long as it is functional and has no evidence of local infection;

7. Life expectancy 12 weeks in the judgement of the Investigator;

8. Eastern Cooperative Oncology Group (ECOG) status of 1 or 0;

9. Female and male patients:

• Female patients of childbearing potential must have a negative pregnancy test upon entry into this study and agree to use a highly effective method of contraception from Screening until 1 month after the last dose of gemcitabine;
• Highly effective methods of contraception that result in a low failure rate (i.e., <1% per year) when used consistently and correctly include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence;
• True abstinence, when in line with the preferred and usual lifestyle of the patient, is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of study participation and for 1 month after the last dose of gemcitabine. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, and post-ovulation method) and withdrawal are not acceptable methods of contraception; and
• Female patients of non-childbearing potential must be either postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile upon entry into the study;
• Male patients must be either surgically sterile or agree to use a double-barrier contraception method from Screening until 6 months after the last dose of gemcitabine; o Where available and in accordance with local practice, male patients must be advised to seek further advice regarding cryoconservation of sperm prior to gemcitabine treatment due to the possibility of infertility after therapy with gemcitabine; and

10. Adequate laboratory values at Screening:

• Hemoglobin 9 g/dL;
• White blood cell count 3500/µL;
• Absolute neutrophil count 1500/µL;
• • Platelet count 100,000/µL;
• International normalized ratio (INR) and activated partial thromboplastin time (aPTT) below the upper limit of normal (ULN). It is expected that patients receiving anticoagulation therapy will not have INR and aPTT results that fall within normal limits. It is not intended to exclude these patients and, therefore, medical discretion is permitted for patients who have clinically acceptable results in regards to their current concomitant anticoagulant therapy;
• Aspartate aminotransferase (AST) 3 × ULN;
• Alanine aminotransferase (ALT) 3 × ULN;
• Total bilirubin 2 × ULN;
• Estimated glomerular filtration rate (calculated using the Modification of Diet in Renal Disease study equation [see Appendix B]) 50 mL/min/1.73 m2; and
• Serum albumin 2.5 g/dL. Exclusion Criteria Patients who meet any of the following criteria will be excluded from participation in the

study:

1. Is "treatment-naïve" (i.e., has not received at least 1 anti-folate and platinum combination regimen);

2. Has previously received 3 or more lines of systemic chemotherapeutic or immunotherapeutic treatment. Treatment that is split between pre-surgical resection and post-surgical resection and is the same regimen will be counted as 1 regimen. Patients meeting this condition should be discussed with the Medical Monitor prior to including the patient in the study;

3. Has previously received treatment with gemcitabine;

4. Has stage IV extrathoracic metastatic disease;

5. Inadequate pulmonary function of clinical significance as per Investigator review;

6. Clinically significant pericardial effusion (i.e., as judged by the Investigator and/or requiring drainage) detected by computed tomography (CT) scan at Screening. Standard of care CT scans completed within 2 weeks prior to Screening may be used in place of the Screening CT scan on a case by-case basis as agreed with the Medical Monitor;

7. Prior therapy(ies), if applicable, must be completed according to the criteria below

prior to vector administration:

• Cytotoxic chemotherapy, at least 21 days from last dose;
• Non-cytotoxic chemotherapy (e.g., small molecule inhibitor), at least 14 days from last dose;
• Monoclonal antibody, at least 30 days from last dose;
• Non-antibody immunotherapy (e.g., tumor vaccine), at least 42 days from last dose;
• Radiotherapy, at least 14 days from last local site radiotherapy;
• Hematopoietic growth factor, at least 14 days from last dose; or
• Study drug, 30 days or 5 half-lives, whichever is longer, from last dose;

8. Patient previously treated with IFNs (e.g., for chronic active hepatitis);

9. Suspected/known hypersensitivity to IFN-a2b or rAd-IFN (including any of its excipients);

10. Known hypersensitivity to celecoxib (including any of its excipients) or sulfonamides;

11. Known hypersensitivity to gemcitabine (including any of its excipients);

12. Impaired cardiac function or clinically significant cardiac disease including the

following:

• New York Heart Association class III or IV congestive heart failure;
• Myocardial infarction within the last 12 months; and
• Patients known to have impaired left ventricular ejection fraction per institutional standards and of clinical significance as per Investigator review;

13. Women who are pregnant or breastfeeding;

14. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, depression, or psychiatric illness/social situations within the last 12 months;

15. Patients with active, known, or suspected auto-immune disease or a syndrome that requires systemic or immunosuppressive agents (oral prednisolone or equivalent at a dose of 10 mg per day is permitted); NOTE: patients with vitiligo, residual hypothyroidism due to auto immune disease only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll;

16. History of asthma, acute rhinitis, nasal polyps, angioneurotic edema, urticaria, or other allergic type reactions after taking acetylsalicylic acid or NSAIDs, including COX-2 inhibitors;

17. History of ulcer disease or gastrointestinal bleeding;

18. Uncontrolled or poorly controlled hypertension (i.e., blood pressure >160/100 mmHg) requiring 3 or more anti-hypertensive drugs;

19. Heart rate corrected QT interval using Fridericia's formula >470 ms on resting 12-lead electrocardiogram (ECG);

20. Patients receiving lithium;

21. Any significant disease which, in the opinion of the Investigator, would place the patient at increased risk of harm if he/she participated in the study;

22. History of a prior malignancy for which treatment was completed <2 years prior to Screening or for which the patient has continued evidence of disease, or concurrent malignancy that is clinically unstable and requires tumor-directed treatment;

23. Has a congenital or acquired immunodeficiency, including patients with known history of infection with human immunodeficiency virus;

24. Has both serum albumin 2.5 to 3.5 g/dL and total bilirubin >1.5 ULN;

25. History of clinically significant inflammatory bowel disease requiring systemic (parenteral) immunosuppressive therapy within 5 years prior to Screening; or

26. History of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Related Conditions & MeSH terms

• Malignant Pleural Mesothelioma
• Mesothelioma
• Mesothelioma, Malignant

Intervention

Biological:
• rAd-IFN
Adenovirus-Delivered Interferon Alpha-2b

Drug:
• Celecoxib Oral Product
400 mg twice daily
• Gemcitabine
1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination

Locations

Country	Name	City	State
Australia	Chris O'Brien Lifehouse	Camperdown	New South Wales
Australia	Monash Medical Centre	Clayton	Victoria
Canada	Institut Universitaire de Cardiologie et de Pneumologie De Quebec	Québec	Sainte-Foy
France	Institut Bergonie	Bordeaux
France	CHRU de Brest - Hopital Augustin Morvan	Brest
France	CHU de Caen - Hopital Cote de Nacre	Caen
France	CHRU de Lille	Lille
France	Institut Curie - Oncologie Medicale	Paris
France	Centre Hospitalier Lyon Sud	Pierre-Bénite
France	CHU de Nantes - Hôpital Nord Laennec	Saint-Herblain	Nantes Cedex 1
France	Centre Hospitalier de Saint-Quentin	Saint-Quentin
Germany	Evangelisches Krankenhaus Hamm	Hamm
Germany	Ludwig-Maximilians-Universitaet Muenchen	Munich	Bavaria
Germany	Universitatsklinikum Regensburg	Regensburg
Italy	Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori	Meldola	Forlì-Cesena (FC)
Italy	Azienda Ospedaliero Universitaria Senese, Cancer Immunotherapy	Siena	Tuscany
Poland	Med Polonia Sp. z o.o.	Poznan
Poland	Centrum Onkologii Instytut im. Marii Sklodowskiej - Curie, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow	Warszawa
Russian Federation	Kursk Regional Clinical Oncology Dispensary	Kursk
Russian Federation	Medicina 24/7	Moscow
Russian Federation	Budget Healthcare Institution of Omsk region Clinical Oncology Dispensary	Omsk
Russian Federation	Petrov National Medical Research Center of Oncology	Saint Petersburg
Russian Federation	State Budget Educational Institution of Higher Professional Education Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of Russian Federation	Saint Petersburg
Russian Federation	Ogarev Mordovia State University	Saransk	The Republic Of Mordovia ;
Russian Federation	Volgograd Regional Clinical Oncology Dispensary	Volgograd
United Kingdom	Beatson, West of Scotland Cancer Centre	Glasgow	Scotland
United Kingdom	Guy's and St. Thomas' NHS Trust	London
United Kingdom	Wythenshawe Hospital UHSM	Manchester
United Kingdom	Churchill Hospital	Oxford
United Kingdom	Derriford Hospital ; Derriford Hospital	Plymouth	Devon
United Kingdom	Royal Marsden Foundation Trust	Sutton	Surrey
United States	Johns Hopkins Kimmel Cancer Center	Baltimore	Maryland
United States	University of Maryland Medical Center	Baltimore	Maryland
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	University of California, Los Angeles (UCLA) - Medical Center	Los Angeles	California
United States	Masonic Cancer Center - University of Minnesota	Minneapolis	Minnesota
United States	New York University (NYU) Clinical Cancer Center	New York	New York
United States	University of Pennsylvania Abramson Cancer Center	Philadelphia	Pennsylvania
United States	Mayo Clinic - Rochester	Rochester	Minnesota
United States	University of California, San Francisco (UCSF)	San Francisco	California
United States	H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Trizell Ltd	University of Pennsylvania

Countries where clinical trial is conducted

United States,  Australia,  Canada,  France,  Germany,  Italy,  Poland,  Russian Federation,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse Events Grade 3 or 4	To evaluate the number of patients with Common Terminology Criteria for Adverse Events Grade 3 or 4	60 months
Other	rAd-IFN-related viral DNA	To evaluate post-treatment levels of rAd-IFN-related viral DNA in biological	60 months
Other	Quality of Life; EQ-5D-5L Health Questionnaire	Change in total score and individual components of the EQ-5D-5L; Assessment of health status including: Mobility; Self-Care; Usual Activities; Pain/ Discomfort; Anxiety/ Depression; Health Status (scale 0-100)	60 months
Other	Quality of Life; Lung Cancer Symptom Scale-Mesothelioma	Change in total score and individual components of the Lung Cancer Symptom Scale-mesothelioma; Assessment of symptoms including: Appetite; Fatigue; Coughing; Shortness of Breath; Pain; Symptom Severity; Normal Activities; Quality of Life	60 months
Other	Adenovirus type 5 neutralizing antibodies	Correlation between the presence of adenovirus type 5 neutralizing antibodies prior to treatment and survival (death from any cause)	60 months
Other	Serum Mesothelin and Fibulin-3	Correlation between pre- and post-treatment levels and treatment outcomes	60 months
Primary	Overall Survival	Time to death (from any cause) from randomization	60 months
Secondary	Survival rate	Number of deaths (from any cause) from randomization	60 months
Secondary	Progression Free Survival	Time from randomization to the time when the modified Response Evaluation Criteria in Solid Tumor criteria for disease progression are first met, or when death from any cause occurs	60 months
Secondary	Best response	Best response after randomization (complete response, partial response, or stable disease)	60 months